Biomarker Panel Predicts HER2 Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for predicting the response to HER2-targeted cancer therapies, such as antibody drug conjugates and immunotoxins, are limited in their ability to account for mechanisms of drug uptake and intracellular action, leading to variability in treatment efficacy.
Innovation Solution
The use of a panel of biomarkers including HER2, EGFR, Rab5, Rab4, Rab11, and HSP90 to determine a compound expression index, which helps in predicting the sensitivity of cancer cells to HER2-targeted therapies by assessing protein expression levels and guiding treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current biomarkers (e.g., HER2 alone) are used to predict response to HER2-targeted therapies, then the diagnostic process is simple and quick, but the predictive accuracy and ability to account for drug uptake mechanisms is insufficient
Solution Approach 1:
The patent segments the predictive biomarker assessment into multiple distinct components: HER2 expression level, EGFR expression level, Rab5 expression level, Rab4 expression level, Rab11 expression level, and HSP90 expression level. Each biomarker is measured and evaluated separately to determine its individual contribution to treatment response prediction, allowing for a comprehensive yet structured assessment of multiple biological factors
Solution Approach 2:
The patent merges multiple biomarker expression levels into a unified predictive model. By combining the expression data from HER2, EGFR, Rab5, Rab4, Rab11, and HSP90, the invention creates a composite biomarker profile that integrates information about target receptor presence, endocytic pathway activity, and chaperone function, thereby improving overall predictive accuracy for therapy response
2Adaptability or versatility
If a single biomarker (HER2) is used for treatment selection, then the treatment decision process is straightforward, but it fails to account for variability in drug uptake and intracellular action mechanisms
Solution Approach 1:
The patent segments the biological assessment into functionally distinct biomarker categories: target engagement (HER2, EGFR), endocytic uptake (Rab5, Rab4, Rab11), and intracellular processing (HSP90). This segmentation allows treatment decisions to be personalized based on the specific functional profile of each patient's tumor, accounting for variability in drug uptake and intracellular action mechanisms
Solution Approach 2:
The patent introduces Rab proteins (Rab5, Rab4, Rab11) as intermediary biomarkers that mediate between the extracellular drug administration and intracellular target engagement. These Rab proteins serve as measurable indicators of endocytic pathway activity, providing insight into how efficiently the antibody drug conjugate will be internalized and delivered to its intracellular target
Data Source
AI summary
The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.